- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03660969
Tillförlitligheten av hjärttroponiner för diagnos av hjärtinfarkt i närvaro av skelettmuskelsjukdom (H&M)
Hjärt- och muskelstudie
Visits to the emergency department (ED) for chest pain are extremely common and require a safe, rapid and efficacious treatment algorithm to exclude a possible AMI. These diagnostic algorithms are partly based on an important laboratory value, which showed growing utility in the diagnostic and prognostic of many cardiovascular diseases in the last years : cardiac troponin.
However, some patients with muscle disease often present with unexplained elevated high-sensitive cardiac Troponin T (hs-cTnT) levels in the absence of cardiac disease. The investigators aim at the characterization of the behaviour of this biomarker and its alternative (high-sensitive cardiac Troponin I), which will have important clinical implications on patients management.
Studieöversikt
Status
Detaljerad beskrivning
Introduction: The detection of cardiomyocyte injury as quantified by blood concentrations of cardiac troponin T (cTnT) or I (cTnI) is central in the diagnosis of acute myocardial infarction (AMI). While multiple cardiac disorders other than AMI may also lead to cardiomyocyte injury and therefore elevations in cTnT and cTnI, latest generations of cTnT and cTnI assays are considered to have near exclusive cardiac-specificity. Overall, both analytes (cTnT and cTnI) seem to have comparable diagnostic accuracy among patients presenting with suspected AMI to the emergency department (ED). However, their use in the diagnosis of AMI in patients with a skeletal muscle disease is questioned, as especially cTnT was found to be elevated in this setting. These increased cTnT levels have been successively attributed to a possible re-expression of cTnT isoforms in the diseased muscle, to a primary cardiac involvement associated with the muscle disease or to a cross-reaction of the hs-cTnT assay with TnT of muscle origin.
Aim: To characterize cTn levels in patients with a skeletal muscle disease to assess their utility in the field of cardiology (through their implication in AMI diagnosis and their diagnostic and prognostic accuracy regarding a possible cardiac involvement) and in the field of neurology (for the detection and risk-stratification of the muscle disorder itself).
Methodology: This study will be conducted at the University Hospital of Basel, at the Kantonsspital Aarau, both in Switzerland, and at the University Hospital of Innsbruck, Austria. A prospective cohort patient will be recruited through the neurology, rheumatology and cardiology clinics of these three hospitals. This prospective cohort of patients presenting with skeletal muscle disease will allow us to systematically screen patients for cTn increases, to investigate the prevalence and characteristics of a possible primary cardiac involvement (as documented by electrocardiogram, echocardiography, magnetic resonance imaging, cTnI, NT-proBNP (N-terminal pro-B-type Natriuretic Peptide) and any available further cardiac testing) and to explore the origins of the elevated cTn levels using muscle biopsies. Furthermore, this prospective cohort will document the role of these biomarkers in the diagnosis, prognosis and risk-stratification of the muscle disease. Patients will receive a 1- and 3-year follow-up visit with blood draw in order to measure cTn and other biomarkers and record the impact of the evolution and treatment of the muscle disease on these levels. Major adverse cardiac events including cardiovascular death, AMI, hospitalization for heart failure, and the development of clinical or subclinical heart failure as quantified by elevated blood concentrations of NT-proBNP will be recorded during follow-up.
Potential significance: Elevated cTnT levels do not only have consequences regarding the diagnosis of AMI but also raise many questions regarding their possible use as a diagnostic, prognostic and risk-stratification marker regarding the different muscle injuries and their possible primary cardiac involvement.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Bern, Schweiz, 3010
- Inselspital Bern
-
-
Basel
-
Basel, Basel, Schweiz, 4056
- University Hospital Basel
-
-
Canton of Aargau
-
Aarau, Canton of Aargau, Schweiz, 5001
- Canton Hospital of Aarau
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Schweiz
- University Hospital Zürich
-
-
-
-
Innsbruck
-
Innsbruck, Innsbruck, Österrike, 6020
- Medical University Innsbruck
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Consecutive participants which have been or currently are in treatment for a muscle disease at the University hospital of Basel, at the Canton Hospital of Aarau, University Hospital of Zürich or Bern or at the Medical University of Innsbruck, or who received a new diagnosis/suspicion of such a disease will be included.
Beskrivning
Inclusion Criteria:
- Diagnostic or suspicion of muscle disease as presence of specified keyword in patient's file or as screened by colleagues of the rheumatology, neuromuscular or other medical clinics.
- Patient consent available
Exclusion Criteria:
- Patient's refusal
- Age <18 years old
- Terminal kidney insufficiency with need for dialysis.
- Temporary exclusion criteria : Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (>100 bpm, <90 systolic BP, evidence of organ dysfunction).
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Jämförelse av cTnT- och cTnI-nivåer mätt med olika hs-cTn-analyser hos patienter med skelettmuskelsjukdom.
Tidsram: 1 år
|
1 år
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Jämförelse av nivåer av cTnT och cTnI mätt med hs-analyser i matchade patienter med och utan skelettmuskelsjukdom.
Tidsram: 1 år
|
1 år
|
|
|
Regressionsmodell av olika patienters egenskaper på nivåer av hs-cTnI och hs-cTnT i samband med skelettmuskelsjukdom kontra ingen skelettmuskelsjukdom.
Tidsram: 1 år
|
1 år
|
|
|
Prognostiskt värde av hs-cTn-nivåer hos patienter med och utan skelettmuskelsjukdom.
Tidsram: 3 år
|
3 år
|
|
|
Karakterisering av cTnT och cTnI på skelettmuskelbiopsier från myopatiska patienter.
Tidsram: 1 år
|
1 år
|
|
|
Characterization of the impact of cTnT and cTnI on the diagnosis and prognosis of muscle diseases
Tidsram: 3 years
|
Prognosis defined as the incidence of Major Cardiovascular Events (MACE is defined as a composite of death, acute myocardial infarction, life-threatening arrhythmia (cardiac arrest, sustained ventricular tachycardia, atrioventricular (AV) -block III), cardiac arrest/reanimation, acute heart failure (requiring admission to a hospital or intra-hospital transfer to the intensive care unit), stroke/transient ischemic attack, pulmonary embolism) |
3 years
|
Andra resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Forskning om utvecklingen av en ny cTnT-analys
Tidsram: 3 år
|
3 år
|
|
Proteinkarakterisering
Tidsram: 3 år
|
3 år
|
|
Hjärttroponin som prediktorer eller screeningverktyg för en hjärtinblandning
Tidsram: 3 år
|
3 år
|
|
Hjärttroponin som prediktor för evolution och terapeutiskt svar på muskelsjukdomen eller muskelregenerering.
Tidsram: 3 år
|
3 år
|
|
Karakterisering av hjärttroponin i sjukdomar av olika etiologier som involverar muskler
Tidsram: 3 år
|
3 år
|
|
Effekten av muskelsymtom på hjärttroponin
Tidsram: 3 år
|
3 år
|
|
Hjärttroponin kontra andra markörer (t.ex. CK) för inflammation/nekros av perifera muskler.
Tidsram: 3 år
|
3 år
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Christian Mueller, MD, University Hospital, Basel, Switzerland
- Huvudutredare: Angelika Hammerer, MD, Canton Hospital Aarau
- Huvudutredare: Julia Wanschitz, MD, Medical University Innsbruck
Publikationer och användbara länkar
Allmänna publikationer
- Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger B, Asslaber M, Radl R, Beer M, Polacin M, Mair J, Szolar D, Berghold A, Quasthoff S, Binder JS, Rainer PP. Elevated Cardiac Troponin T in Patients With Skeletal Myopathies. J Am Coll Cardiol. 2018 Apr 10;71(14):1540-1549. doi: 10.1016/j.jacc.2018.01.070.
- Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol. 2011 Oct 18;58(17):1819-24. doi: 10.1016/j.jacc.2011.08.026. Epub 2011 Sep 29.
- du Fay de Lavallaz J, Prepoudis A, Wendebourg MJ, Kesenheimer E, Kyburz D, Daikeler T, Haaf P, Wanschitz J, Loscher WN, Schreiner B, Katan M, Jung HH, Maurer B, Hammerer-Lercher A, Mayr A, Gualandro DM, Acket A, Puelacher C, Boeddinghaus J, Nestelberger T, Lopez-Ayala P, Glarner N, Shrestha S, Manka R, Gawinecka J, Piscuoglio S, Gallon J, Wiedemann S, Sinnreich M, Mueller C; BASEL XII Investigators. Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T. Circulation. 2022 Jun 14;145(24):1764-1779. doi: 10.1161/CIRCULATIONAHA.121.058489. Epub 2022 Apr 7.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Smärta
- Neurologiska manifestationer
- Muskuloskeletala sjukdomar
- Sjukdomar i nervsystemet
- Muskelhypertoni
- Neuromuskulära manifestationer
- Patologiska processer
- Patologiska tillstånd, anatomiska
- Neuromuskulära sjukdomar
- Muskuloskeletal smärta
- Atrofi
- Patologiska tillstånd, tecken och symtom
- Tecken och symtom
- Muskelspasticitet
- Muskelsvaghet
- Muskelsjukdomar
- Muskelatrofi
- Muskelvärk
- Muskelkramp
Andra studie-ID-nummer
- BASEL XII
- Research Grant (Annat bidrag/finansieringsnummer: Swiss Heart Foundation)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .